{
    "organizations": [],
    "uuid": "c56a0cbafe39bf12479bcdd5dd2030b1f2a88318",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-hemispherx-enters-sale-leaseback-a/brief-hemispherx-enters-sale-leaseback-agreement-for-nj-development-and-production-facility-idUSFWN1PC0T2",
    "ord_in_thread": 0,
    "title": "BRIEF-Hemispherx Enters Sale/Leaseback Agreement For NJ Development And Production Facility",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 17 (Reuters) - Hemispherx Biopharma Inc:\n* HEMISPHERX ENTERS INTO SALE/LEASEBACK AGREEMENT FOR NJ DEVELOPMENT AND PRODUCTION FACILITY\n* HEMISPHERX BIOPHARMA INC - UNDER TERMS OF AGREEMENT, HEMISPHERX IS SELLING THE REAL ESTATE FOR $4.0 MILLION\n* HEMISPHERX BIOPHARMA - UNDER TERMS OF AGREEMENT, SIMULTANEOUSLY ENTERING INTO A 10-YEAR LEASE WITH OPTIONS TO EXTEND LEASE FOR ANOTHER 10-YEARS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-17T21:39:00.000+02:00",
    "crawled": "2018-01-18T16:01:39.013+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "hemispherx",
        "biopharma",
        "inc",
        "hemispherx",
        "enters",
        "agreement",
        "nj",
        "development",
        "production",
        "facility",
        "hemispherx",
        "biopharma",
        "inc",
        "term",
        "agreement",
        "hemispherx",
        "selling",
        "real",
        "estate",
        "million",
        "hemispherx",
        "biopharma",
        "term",
        "agreement",
        "simultaneously",
        "entering",
        "lease",
        "option",
        "extend",
        "lease",
        "another",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}